Novel therapies for diabetic neuropathic pain and central nervous system diseases

 NeuroBo is focused on neurodegenerative diseases that affect millions of patients worldwide.


NeuroBo Pharmaceuticals' novel lead candidate NB-01 is targeting diabetic neuropathic pain. NB-01 increases levels of the neurotrophin, nerve growth factor (NGF). NGF inhibits nerve cell death and promotes nerve regeneration. The compound, licensed from leading pharmaceutical company, Dong-A ST, is initiating a Phase III clinical trial in early 2019. NeuroBo Pharmaceuticals has a second compound focusing on Alzheimer's disease currently ready for an IND and a Phase IIa trial.

NeuroBo Pharmaceuticals was jointly founded by JK BioPharma Solutions, a company specializing in the development of new biopharmaceuticals, and Dr. Roy Freeman, a Harvard Medical School neurologist, to develop natural ethical medicines focused on neuroscience.



The NeuroBo team hails from various organizations within the pharmaceutical, diabetes, and biotech industries, yet the NeuroBo team has one shared goal: to bring life-changing and disease-modifying therapies to patients suffering from neurodegenerative diseases worldwide.  

With John L. Brooks III, a well-known executive within the life sciences industry, at the helm of the company, along with Dr. Mark Versavel, experienced senior clinical drug developer and clinical pharmacologist, and Dr. Nandan Padukone, a well-known biotech executive, NeuroBo is poised to revolutionize the way we approach treatments for neurodegenerative diseases.